Study Title
MK-3475-051: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma
Protocol ID
MK-3475-051
Condition/s
Melanoma
Lymphoma
Solid Tumor
Classical Hodgkin Lymphoma
Microsatellite-instability-high Solid Tumor
Lymphoma
Solid Tumor
Classical Hodgkin Lymphoma
Microsatellite-instability-high Solid Tumor
Diagnosis Stage
Relapse/ refractory
Location
NSW
Sponsor
Merck Sharp & Dohme Corp.
Links
Trial Status
Closed to Recruitment
Sites
Sydney Children's Hospital
The Children's Hospital at Westmead
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
6 months to 17 years
International registry ID's
NCT02332668
| Study Title | MK-3475-051: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced and relapsed or refractory solid tumor or lymphoma |
|---|---|
| Protocol ID | MK-3475-051 |
| Disease (Sub Disease) | Melanoma Lymphoma Solid Tumor Classical Hodgkin Lymphoma Microsatellite-instability-high Solid Tumor |
| Diagnosis Stage | Relapse/ refractory |
| Location | NSW |
| Sponsor | Merck Sharp & Dohme Corp. |
| Links | https://clinicaltrials.gov/ct2/show/NCT02332668 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 04/04/2016 |
| Sites | Sydney Children's Hospital / The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 6 months to 17 years |
| International registry ID's | NCT02332668 |